Archive · 16 Aug 2025
Weight-Loss Drugs Linked to Serious Eye, Mental Health Risks
Some weight loss drugs, like Ozempic, are used to help people manage their weight.
But new research is raising some concerns.
Studies suggest that these drugs may be linked to a higher chance of getting serious eye problems, like losing your vision suddenly.
There are also worries that these drugs could affect people's mental health, potentially leading to feelings of depression or even thoughts of harming themselves.
These findings mean doctors and researchers need to keep a close eye on these drugs to make sure they are as safe as possible.
GLP-1 agonists like Ozempic, Wegovy, and Mounjaro are used to manage diabetes and obesity.
New studies suggest increased risk of serious eye conditions with GLP-1 agonists.
Non-arteritic anterior ischaemic optic neuropathy (NAION) is a possible eye condition linked to the drugs.
NAION is a sudden and painless vision loss due to reduced blood flow to the optic nerve.
A study highlighted the potential for mental health risks, including depression, with GLP-1 agonists.
- Who
- Individuals using weight-loss drugs, researchers, and medical professionals.
- What
- Potential risks of serious eye conditions and mental health issues linked to weight loss drugs such as Ozempic.
- When
- Recent studies published on the potential risks of GLP-1 agonists.
- Where
- Not explicitly stated, but studies and discussions occurring in the medical and scientific communities.
- Why
- To assess the safety and long-term effects of GLP-1 agonists for treating obesity and diabetes.
- Drug Types
- GLP-1 agonists (Ozempic, Wegovy, Mounjaro)
- Eye Condition
- NAION (Non-arteritic anterior ischaemic optic neuropathy)
- Action
- GLP-1 agonists mimic the hormone GLP-1
- Primary Use
- Managing diabetes and obesity